RAMA PHARMA LIMITED

Company Registration Number:
11186456 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2023

Period of accounts

Start date: 01 January 2023

End date: 31 December 2023

RAMA PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2023

Balance sheet
Notes

RAMA PHARMA LIMITED

Balance sheet

As at 31 December 2023


Notes

2023

8 months to 31 December 2022


£

£
Fixed assets
Investments: 3 182,307 182,307
Total fixed assets: 182,307 182,307
Current assets
Debtors: 4 1,000,000 1,697,148
Cash at bank and in hand: 70,625 56,205
Total current assets: 1,070,625 1,753,353
Creditors: amounts falling due within one year: 5 (191,040) (692,712)
Net current assets (liabilities): 879,585 1,060,641
Total assets less current liabilities: 1,061,892 1,242,948
Creditors: amounts falling due after more than one year: 6 (434,750) (615,520)
Total net assets (liabilities): 627,142 627,428
Capital and reserves
Called up share capital: 4 4
Share premium account: 540,000 540,000
Profit and loss account: 87,138 87,424
Shareholders funds: 627,142 627,428

The notes form part of these financial statements

RAMA PHARMA LIMITED

Balance sheet statements

For the year ending 31 December 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 23 September 2024
and signed on behalf of the board by:

Name: A Tanna
Status: Director

The notes form part of these financial statements

RAMA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

RAMA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

2. Employees

2023 8 months to 31 December 2022
Average number of employees during the period 3 3

RAMA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

3. Fixed investments

Investments in equity shares which are not publicly traded or where fair value cannot be measured reliably are measured at cost less impairment

RAMA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

4. Debtors

2023 8 months to 31 December 2022
££
Debtors due after more than one year: 1,000,000 1,697,148

RAMA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

5. Creditors: amounts falling due within one year note

2023 2022 Bank borrowings - 378,890 owed to directors 189,684 235,598 Amounts due to related parties - 77,000 Accrued expenses 1,356 1,224 Total creditors due within one year 191,040 692,712

RAMA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

6. Creditors: amounts falling due after more than one year note

2023 2022 Amounts owed to related parties 434,750 615,520

RAMA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

7. Related party transactions

Name of the related party:
Relationship:
Directors
Description of the Transaction: Amount owing to directors There are no fixed repayment terms and no interest is charged on the loan
£
Balance at 01 January 2023 235,598
Balance at 31 December 2023 189,684
Name of the related party:
Relationship:
Parent
Description of the Transaction: Owing to Parent Initial loan was for £770,000 it is repayable: Years 1-4: £77,000 per annum Year 5: £384,520 at the end of year 5 No interest is charged on this loan
£
Balance at 01 January 2023 692,520
Balance at 31 December 2023 434,750

Key management personnel are considered to be the directors of the company